LON:RENX Renalytix (RENX) Share Price, News & Analysis GBX 1.87 -0.03 (-1.58%) As of 11:36 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesBuy This Stock About Renalytix Stock (LON:RENX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Renalytix alerts:Sign Up Key Stats Today's Range 1.80▼ 1.9350-Day Range 1.60▼ 252-Week Range 1.60▼ 15.50Volume194,919 shsAverage Volume834,957 shsMarket Capitalization£8.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com. Read More Receive RENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RENX Stock News HeadlinesRenalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision InterventionMay 12, 2026 | tmcnet.comRenalytix shares fall 25% as revenues miss expectationsFebruary 11, 2026 | finance.yahoo.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free.June 23 at 1:00 AM | Behind the Markets (Ad)Renalytix expands kidney disease test adoption and strategic partnershipsDecember 9, 2025 | msn.comRenalytix’s KidneyIntelX.dkd Test Gains Recognition for Advancing CKD ManagementNovember 12, 2025 | msn.comRenalytix Seeks CE Mark for KidneyIntelX.dkd Amid Growing Global InterestOctober 1, 2025 | msn.comRenalytix shares slump as revenue guidance revised after Tempus dealSeptember 23, 2025 | lse.co.ukRenalytix Plc Announces £500,000 Retail Offer to Bolster Financial PositionSeptember 22, 2025 | tipranks.comSee More Headlines RENX Stock Analysis - Frequently Asked Questions How have RENX shares performed this year? Renalytix's stock was trading at GBX 5.80 at the beginning of the year. Since then, RENX stock has decreased by 67.8% and is now trading at GBX 1.87. How were Renalytix's earnings last quarter? Renalytix Plc (LON:RENX) released its quarterly earnings data on Tuesday, October, 1st. The company reported ($31.00) earnings per share for the quarter. Renalytix had a negative net margin of 680.00% and a positive trailing twelve-month return on equity of 274.67%. How do I buy shares of Renalytix? Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include AutoZone (AZO), Beyond Meat (BYND), Helium One Global (HE1), HSBC (HSBA), Intel (INTC), ITM Power (ITM) and JD Sports Fashion (JD). Company Calendar Last Earnings10/01/2024Today6/23/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:RENX CIKN/A Webwww.renalytixai.com Phone44 20 3139 2910FaxN/AEmployees102Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (4) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£109.93 million Net Margins-680.00% Pretax MarginN/A Return on Equity274.67% Return on Assets-93.54% Debt Debt-to-Equity Ratio-118.57 Current Ratio1.21 Quick Ratio2.42 Sales & Book Value Annual Sales£3.30 million Price / Sales2.48 Cash FlowGBX 1.02 per share Price / Cash Flow1.84 Book ValueGBX (10.71) per share Price / Book-0.17Miscellaneous Outstanding Shares437,019,000Free FloatN/AMarket Cap£8.17 million OptionableNot Optionable Beta1.81 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:RENX) was last updated on 6/23/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
